Symbols / ZYME Stock $23.90 -0.54% Zymeworks Inc.

Healthcare • Biotechnology • United States • NMS
ZYME (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Kenneth H. Galbraith C.A.
Exch · Country NMS · United States
Market Cap 1.76B
Enterprise Value 1.41B
Income -102.66M
Sales 81.26M
FCF (ttm) -45.50M
Book/sh 3.60
Cash/sh 5.00
Employees 243
Insider 10d —
IPO Apr 28, 2017
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E 46.34
PEG —
P/S 21.64
P/B 6.64
P/C —
EV/EBITDA -13.05
EV/Sales 17.32
Quick Ratio 10.36
Current Ratio 10.82
Debt/Eq 10.42
LT Debt/Eq —
EPS (ttm) -1.37
EPS next Y 0.52
EPS Growth —
Revenue Growth -91.10%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-06
Earnings (prior) 2026-05-07
ROA -15.78%
ROE -42.02%
ROIC —
Gross Margin -67.01%
Oper. Margin -19.57%
Profit Margin -126.33%
Shs Outstand 73.02M
Shs Float 68.14M
Insider Own 1.27%
Instit Own 99.62%
Short Float 9.42%
Short Ratio 7.62
Short Interest 4.65M
52W High 29.75
vs 52W High -19.66%
52W Low 10.93
vs 52W Low 118.66%
Beta 1.19
Impl. Vol. 37.23%
Rel Volume 1.08
Avg Volume 661.92K
Volume 714.80K
Target (mean) $40.15
Tgt Median $40.00
Tgt Low $31.00
Tgt High $58.00
# Analysts 13
Recom Strong_buy
Prev Close $24.03
Price $23.90
Change -0.54%
About

Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$40.15
Mean price target
2. Current target
$23.90
Latest analyst target
3. DCF / Fair value
$-11.22
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$23.90
Low
$31.00
High
$58.00
Mean
$40.15

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-08 main Wells Fargo Overweight → Overweight $34
2026-03-09 main Evercore ISI Group Outperform → Outperform $48
2026-03-06 main HC Wainwright & Co. Buy → Buy $46
2026-03-03 main Stifel Buy → Buy $47
2026-03-03 main Leerink Partners Outperform → Outperform $58
2025-12-17 init Truist Securities — → Buy $40
2025-12-12 up Wells Fargo Equal-Weight → Overweight $33
2025-12-03 init Citizens — → Market Outperform $32
2025-11-21 reit B. Riley Securities Buy → Buy $40
2025-11-19 main Wells Fargo Equal-Weight → Equal-Weight $25
2025-11-19 main Stifel Buy → Buy $40
2025-11-18 main HC Wainwright & Co. Buy → Buy $32
2025-11-07 main Wells Fargo Equal-Weight → Equal-Weight $17
2025-10-16 main JP Morgan Overweight → Overweight $23
2025-10-14 up HC Wainwright & Co. Neutral → Buy $26
2025-10-10 init B. Riley Securities — → Buy $30
2025-08-11 main Citigroup Buy → Buy $22
2025-07-03 reit HC Wainwright & Co. Neutral → Neutral $13
2025-05-20 init TD Securities — → Buy —
2025-03-11 init LifeSci Capital — → Outperform $30
News
RSS: Latest ZYME news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-01-12 SMITH JEFFREY T L MD, FRCP Officer — 17,666 — —
2026-01-12 GALBRAITH KENNETH HARRY Chief Executive Officer — 64,000 — —
2026-01-12 MOORE PAUL ANDREW Officer — 17,666 — —
2026-01-12 HOLLYWOOD MARK Chief Operating Officer — 17,666 — —
2026-01-12 SMITH JEFFREY T L MD, FRCP Officer — 9,310 $22.67 $211,090
2026-01-12 GALBRAITH KENNETH HARRY Chief Executive Officer — 30,424 $22.67 $689,819
2026-01-12 MOORE PAUL ANDREW Officer — 9,560 $22.67 $216,759
2026-01-12 HOLLYWOOD MARK Chief Operating Officer — 6,120 $22.67 $138,762
2026-01-06 PATTERSON LEONE D. CPA Chief Financial Officer — 459 $24.18 $11,099
2026-01-05 SMITH JEFFREY T L MD, FRCP Officer — 20,000 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
105.97
+38.87%
76.30
+0.38%
76.01
-81.57%
412.48
Operating Revenue
105.97
+38.87%
76.30
+0.38%
76.01
-81.57%
412.48
Operating Expense
198.50
+1.21%
196.12
-8.36%
214.02
-24.11%
282.00
Research And Development
137.00
+1.77%
134.62
-6.27%
143.62
-31.15%
208.60
Selling General And Administration
61.50
+0.00%
61.50
-12.64%
70.40
-4.09%
73.40
General And Administrative Expense
61.50
+0.00%
61.50
-12.64%
70.40
-4.09%
73.40
Salaries And Wages
30.90
+18.39%
26.10
+17.04%
22.30
-6.30%
23.80
Other Gand A
30.60
-13.56%
35.40
-26.40%
48.10
-3.02%
49.60
Total Expenses
198.50
+1.21%
196.12
-8.36%
214.02
-24.11%
282.00
Operating Income
-92.53
+22.77%
-119.82
+13.18%
-138.01
-205.76%
130.49
Total Operating Income As Reported
-92.55
+32.50%
-137.11
+0.68%
-138.05
-205.77%
130.53
EBITDA
-81.42
+25.04%
-108.62
+10.01%
-120.70
-184.71%
142.49
Normalized EBITDA
-80.81
+12.27%
-92.11
+22.93%
-119.52
-184.56%
141.34
Reconciled Depreciation
11.11
-0.74%
11.19
-35.32%
17.30
+44.16%
12.00
EBIT
-92.53
+22.77%
-119.82
+13.18%
-138.01
-205.76%
130.49
Total Unusual Items
-0.61
+96.31%
-16.51
-1293.33%
-1.19
-202.86%
1.15
Total Unusual Items Excluding Goodwill
-0.61
+96.31%
-16.51
-1293.33%
-1.19
-202.86%
1.15
Special Income Charges
0.00
+100.00%
-17.29
0.00
0.00
Impairment Of Capital Assets
0.00
-100.00%
17.29
0.00
0.00
Net Income
-81.13
+33.88%
-122.69
-3.39%
-118.67
-195.44%
124.34
Pretax Income
-79.75
+31.61%
-116.61
+2.21%
-119.24
-188.17%
135.23
Net Non Operating Interest Income Expense
13.35
-33.03%
19.94
+1.20%
19.70
+447.97%
3.60
Net Interest Income
13.35
-33.03%
19.94
+1.20%
19.70
+447.97%
3.60
Interest Income Non Operating
13.35
-33.03%
19.94
+1.20%
19.70
+447.97%
3.60
Interest Income
13.35
-33.03%
19.94
+1.20%
19.70
+447.97%
3.60
Other Income Expense
-0.56
+96.66%
-16.73
-1771.25%
-0.89
-180.54%
1.11
Other Non Operating Income Expenses
0.05
+123.39%
-0.22
-174.91%
0.29
+792.86%
-0.04
Gain On Sale Of Security
-0.61
-178.61%
0.78
+165.49%
-1.19
-202.86%
1.15
Tax Provision
1.38
-77.38%
6.08
+1171.13%
-0.57
-105.21%
10.89
Tax Rate For Calcs
0.00
+0.00%
0.00
+4308.99%
0.00
-94.09%
0.00
Tax Effect Of Unusual Items
-0.13
+96.31%
-3.47
-61326.42%
-0.01
-106.08%
0.09
Net Income Including Noncontrolling Interests
-81.13
+33.88%
-122.69
-3.39%
-118.67
-195.44%
124.34
Net Income From Continuing Operation Net Minority Interest
-81.13
+33.88%
-122.69
-3.39%
-118.67
-195.44%
124.34
Net Income From Continuing And Discontinued Operation
-81.13
+33.88%
-122.69
-3.39%
-118.67
-195.44%
124.34
Net Income Continuous Operations
-81.13
+33.88%
-122.69
-3.39%
-118.67
-195.44%
124.34
Normalized Income
-80.65
+26.45%
-109.65
+6.68%
-117.49
-195.31%
123.28
Net Income Common Stockholders
-81.13
+33.88%
-122.69
-3.39%
-118.67
-195.44%
124.34
Otherunder Preferred Stock Dividend
—
—
—
0.23
Diluted EPS
-1.08
+33.33%
-1.62
+5.81%
-1.72
-190.53%
1.90
Basic EPS
-1.08
+33.33%
-1.62
+5.81%
-1.72
-190.05%
1.91
Basic Average Shares
75.40
-0.58%
75.85
+10.14%
68.86
+5.63%
65.19
Diluted Average Shares
75.41
-0.61%
75.88
+10.19%
68.86
+5.54%
65.25
Diluted NI Availto Com Stockholders
-81.33
+33.64%
-122.56
-3.27%
-118.67
-195.62%
124.11
Average Dilution Earnings
-0.20
-240.00%
0.14
0.00
+100.00%
-0.23
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
346.53
-25.17%
463.09
-20.28%
580.88
-10.46%
648.73
Current Assets
248.77
-17.20%
300.45
-27.24%
412.93
-24.19%
544.71
Cash Cash Equivalents And Short Term Investments
228.80
+1.34%
225.78
-39.68%
374.33
-23.95%
492.23
Cash And Cash Equivalents
41.16
-37.74%
66.10
-58.05%
157.56
-60.70%
400.91
Cash Equivalents
32.19
+2.24%
31.48
—
—
Cash Financial
8.97
-74.10%
34.62
—
—
Other Short Term Investments
187.64
+17.52%
159.67
-26.34%
216.77
+137.37%
91.32
Receivables
4.64
-91.69%
55.81
+186.57%
19.48
-41.69%
33.40
Accounts Receivable
4.64
-91.69%
55.81
+186.57%
19.48
-41.69%
33.40
Prepaid Assets
—
—
—
—
Other Current Assets
15.33
-18.71%
18.86
-1.37%
19.12
+0.25%
19.07
Total Non Current Assets
97.76
-39.89%
162.64
-3.16%
167.95
+61.46%
104.02
Net PPE
31.23
-9.00%
34.32
-8.60%
37.54
-21.21%
47.65
Gross PPE
52.10
-0.08%
52.15
-10.40%
58.20
-4.51%
60.95
Accumulated Depreciation
-20.88
-17.08%
-17.83
+13.68%
-20.66
-55.32%
-13.30
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
6.76
-2.90%
6.96
-8.22%
7.58
+4.18%
7.28
Construction In Progress
0.54
0.00
-100.00%
0.12
+60.53%
0.08
Other Properties
29.56
-1.45%
30.00
+1.67%
29.50
-9.60%
32.63
Leases
15.24
+0.35%
15.19
-27.64%
20.99
+0.15%
20.96
Goodwill And Other Intangible Assets
13.37
-19.44%
16.59
-55.52%
37.30
-2.86%
38.40
Goodwill
12.02
+0.00%
12.02
+0.00%
12.02
+0.00%
12.02
Other Intangible Assets
1.35
-70.50%
4.58
-81.90%
25.28
-4.17%
26.38
Investments And Advances
41.79
-57.55%
98.43
+20.14%
81.93
+9147.18%
0.89
Non Current Deferred Assets
4.71
+7.34%
4.38
+21.30%
3.62
+166.79%
1.35
Non Current Deferred Taxes Assets
4.71
+7.34%
4.38
+21.30%
3.62
+168.77%
1.34
Non Current Prepaid Assets
—
—
7.24
-53.97%
15.73
Other Non Current Assets
6.67
-25.17%
8.92
+17.88%
7.57
—
Total Liabilities Net Minority Interest
78.03
-37.24%
124.32
+7.11%
116.07
-25.48%
155.77
Current Liabilities
42.32
-52.07%
88.29
+58.34%
55.76
-41.69%
95.62
Payables And Accrued Expenses
26.76
-49.01%
52.48
+34.15%
39.12
-47.09%
73.94
Payables
4.91
-7.01%
5.28
-34.18%
8.02
-70.05%
26.79
Accounts Payable
4.40
+12.81%
3.90
-37.17%
6.21
-21.00%
7.86
Other Payable
—
—
0.73
-60.36%
1.84
Current Accrued Expenses
21.85
-53.72%
47.20
+51.78%
31.10
-34.06%
47.16
Pensionand Other Post Retirement Benefit Plans Current
8.83
+41.88%
6.22
+1.12%
6.15
-57.17%
14.37
Total Tax Payable
0.51
-63.13%
1.38
-23.91%
1.81
-89.40%
17.08
Income Tax Payable
0.08
-35.16%
0.13
-92.93%
1.81
+115.60%
0.84
Current Debt And Capital Lease Obligation
3.47
+26.68%
2.74
-35.70%
4.26
+28.27%
3.32
Current Capital Lease Obligation
3.47
+26.68%
2.74
-35.70%
4.26
+28.27%
3.32
Current Deferred Liabilities
2.42
-90.55%
25.59
+591.75%
3.70
+57.20%
2.35
Current Deferred Revenue
2.42
-90.55%
25.59
+591.75%
3.70
+57.20%
2.35
Other Current Liabilities
0.84
-33.23%
1.26
-50.04%
2.53
+54.08%
1.64
Total Non Current Liabilities Net Minority Interest
35.71
-0.89%
36.03
-40.26%
60.31
+0.28%
60.14
Long Term Debt And Capital Lease Obligation
14.80
-6.15%
15.77
-29.81%
22.46
-9.40%
24.79
Long Term Capital Lease Obligation
14.80
-6.15%
15.77
-29.81%
22.46
-9.40%
24.79
Non Current Deferred Liabilities
20.63
+6.54%
19.37
-46.56%
36.24
+11.94%
32.38
Non Current Deferred Revenue
14.61
-0.01%
14.61
-55.66%
32.94
+7.69%
30.59
Non Current Deferred Taxes Liabilities
6.03
+26.61%
4.76
+44.27%
3.30
+84.56%
1.79
Other Non Current Liabilities
0.28
-68.94%
0.90
-44.38%
1.61
-45.95%
2.98
Stockholders Equity
268.50
-20.74%
338.77
-27.12%
464.81
-5.71%
492.96
Common Stock Equity
268.50
-20.74%
338.77
-27.12%
464.81
-5.71%
492.96
Capital Stock
1,113.11
+8.72%
1,023.81
+1.71%
1,006.57
+11.01%
906.76
Common Stock
1,113.11
+8.72%
1,023.81
+1.71%
1,006.57
+11.01%
906.76
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
75.19
+9.03%
68.96
-1.64%
70.12
+11.19%
63.06
Ordinary Shares Number
75.19
+9.03%
68.96
-1.64%
70.12
+11.19%
63.06
Additional Paid In Capital
114.63
-24.71%
152.25
+7.01%
142.27
-6.16%
151.61
Retained Earnings
-953.16
-14.79%
-830.34
-22.57%
-677.44
-21.24%
-558.76
Gains Losses Not Affecting Retained Earnings
-6.08
+12.56%
-6.95
-5.29%
-6.60
+0.84%
-6.66
Other Equity Adjustments
-6.08
+12.56%
-6.95
-5.29%
-6.60
+0.84%
-6.66
Total Equity Gross Minority Interest
268.50
-20.74%
338.77
-27.12%
464.81
-5.71%
492.96
Total Capitalization
268.50
-20.74%
338.77
-27.12%
464.81
-5.71%
492.96
Working Capital
206.45
-2.69%
212.16
-40.60%
357.16
-20.47%
449.08
Invested Capital
268.50
-20.74%
338.77
-27.12%
464.81
-5.71%
492.96
Total Debt
18.27
-1.29%
18.51
-30.75%
26.72
-4.95%
28.11
Capital Lease Obligations
18.27
-1.29%
18.51
-30.75%
26.72
-4.95%
28.11
Net Tangible Assets
255.13
-20.81%
322.18
-24.64%
427.51
-5.95%
454.56
Tangible Book Value
255.13
-20.81%
322.18
-24.64%
427.51
-5.95%
454.56
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-33.01
+70.01%
-110.06
+6.99%
-118.32
-182.11%
144.11
Cash Flow From Continuing Operating Activities
-33.01
+70.01%
-110.06
+6.99%
-118.32
-182.11%
144.11
Net Income From Continuing Operations
-81.13
+33.88%
-122.69
-3.39%
-118.67
-195.44%
124.34
Depreciation Amortization Depletion
11.11
-0.74%
11.19
-35.32%
17.30
+44.16%
12.00
Depreciation
7.05
+5.33%
6.70
-54.14%
14.60
+32.89%
10.99
Amortization Cash Flow
4.06
-9.79%
4.50
+66.40%
2.70
+166.21%
1.01
Depreciation And Amortization
11.11
-0.74%
11.19
-35.32%
17.30
+44.16%
12.00
Amortization Of Intangibles
4.06
-9.79%
4.50
+66.40%
2.70
+166.21%
1.01
Other Non Cash Items
—
-1.88
-398.10%
0.63
+352.00%
-0.25
Stock Based Compensation
28.03
+57.57%
17.79
+119.60%
8.10
+101.79%
4.01
Asset Impairment Charge
0.00
-100.00%
17.29
0.00
0.00
Deferred Tax
0.94
+36.76%
0.69
+191.28%
-0.76
-139.02%
1.94
Deferred Income Tax
0.94
+36.76%
0.69
+191.28%
-0.76
-139.02%
1.94
Operating Gains Losses
0.53
+135.92%
-1.48
-4677.42%
-0.03
+98.42%
-1.96
Unrealized Gain Loss On Investment Securities
0.00
0.00
-100.00%
0.67
0.00
Net Foreign Currency Exchange Gain Loss
0.53
+135.92%
-1.48
-4677.42%
-0.03
+98.42%
-1.96
Change In Working Capital
7.50
+124.23%
-30.97
-21.13%
-25.57
-736.76%
4.01
Change In Receivables
51.20
+240.82%
-36.36
-361.16%
13.92
+179.51%
-17.51
Changes In Account Receivables
51.20
+240.82%
-36.36
-361.16%
13.92
+179.51%
-17.51
Change In Prepaid Assets
6.51
+361.51%
-2.49
-157.95%
4.29
+308.60%
-2.06
Change In Payables And Accrued Expense
-23.69
-287.46%
12.64
+128.84%
-43.82
-260.40%
27.32
Change In Payable
-23.69
-287.46%
12.64
+128.84%
-43.82
-260.40%
27.32
Change In Account Payable
-23.65
-265.13%
14.32
+131.97%
-44.79
-269.15%
26.48
Change In Other Working Capital
-23.17
-751.76%
3.56
-3.89%
3.70
—
Change In Other Current Liabilities
-3.34
+59.80%
-8.31
-126.95%
-3.66
+1.95%
-3.74
Investing Cash Flow
26.66
-31.20%
38.76
+118.70%
-207.25
-284.88%
-53.85
Cash Flow From Continuing Investing Activities
26.66
-31.20%
38.76
+118.70%
-207.25
-284.88%
-53.85
Net PPE Purchase And Sale
-1.52
+23.61%
-1.99
+19.52%
-2.47
+69.64%
-8.15
Purchase Of PPE
-1.52
+23.61%
-1.99
+19.52%
-2.47
+69.64%
-8.15
Capital Expenditure
-2.35
+23.29%
-3.07
+24.80%
-4.08
+68.94%
-13.12
Net Investment Purchase And Sale
29.02
-30.62%
41.82
+120.58%
-203.18
-398.91%
-40.72
Purchase Of Investment
-196.06
+30.90%
-283.74
+48.71%
-553.25
-389.58%
-113.00
Sale Of Investment
225.08
-30.87%
325.56
-7.00%
350.07
+384.32%
72.28
Net Intangibles Purchase And Sale
-0.83
+22.70%
-1.07
+32.94%
-1.60
+67.78%
-4.97
Purchase Of Intangibles
-0.83
+22.70%
-1.07
+32.94%
-1.60
+67.78%
-4.97
Financing Cash Flow
-18.56
+9.19%
-20.44
-124.96%
81.87
-24.60%
108.58
Cash Flow From Continuing Financing Activities
-18.56
+9.19%
-20.44
-124.96%
81.87
-24.60%
108.58
Net Issuance Payments Of Debt
—
-0.01
+33.33%
-0.02
-50.00%
-0.01
Repayment Of Debt
—
-0.01
+33.33%
-0.02
-50.00%
-0.01
Long Term Debt Payments
—
-0.01
+33.33%
-0.02
-50.00%
-0.01
Net Long Term Debt Issuance
—
-0.01
+33.33%
-0.02
-50.00%
-0.01
Net Common Stock Issuance
-36.71
-22.15%
-30.05
-139.49%
76.09
-29.24%
107.53
Common Stock Payments
-41.70
-38.75%
-30.05
0.00
0.00
Repurchase Of Capital Stock
-41.70
-38.75%
-30.05
0.00
0.00
Proceeds From Stock Option Exercised
18.33
+87.28%
9.79
+67.99%
5.83
+251.39%
1.66
Net Other Financing Charges
-0.18
-4.02%
-0.17
-228.30%
-0.05
+91.11%
-0.60
Changes In Cash
-24.90
+72.86%
-91.74
+62.36%
-243.71
-222.56%
198.84
Effect Of Exchange Rate Changes
-0.04
-115.73%
0.29
-19.21%
0.35
+74.38%
0.20
Beginning Cash Position
66.10
-58.05%
157.56
-60.70%
400.91
+98.60%
201.87
End Cash Position
41.16
-37.74%
66.10
-58.05%
157.56
-60.70%
400.91
Free Cash Flow
-35.36
+68.74%
-113.12
+7.58%
-122.40
-193.45%
130.98
Income Tax Paid Supplemental Data
1.35
-57.53%
3.18
+1826.67%
0.17
-98.35%
10.00
Change In Income Tax Payable
-0.04
+97.32%
-1.68
-273.40%
0.97
+15.48%
0.84
Change In Tax Payable
-0.04
+97.32%
-1.68
-273.40%
0.97
+15.48%
0.84
Common Stock Issuance
4.99
0.00
-100.00%
76.09
-29.24%
107.53
Issuance Of Capital Stock
4.99
0.00
-100.00%
76.09
-29.24%
107.53
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category